By: IPP Bureau
Last updated : August 06, 2024 11:07 am
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
UK Relonchem Ltd, receives marketing authorization for the product Levonorgestrel 1.5 mg Tablets
Marksans Pharma Limited announces that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA.
Levonorgestrel, also known as the morning-after pill, is a first-line oral emergency contraceptive pill. It is to be used within 72 hours of unprotected sexual intercourse or when a presumed contraceptive failure has occurred.